A review of valproate in psychiatric practice

Bibliography

• National Institute for Health and Clinical Excellence 2004. The epilepsies. The diagnosis and management of the epilepsies in adults and children in primary and secondary care. Clinical Guideline 20. Available from: www.nice.org.uk
   Google Scholar
• Burton BS. On the propyl derivatives and decomposition products of ethylacetoacetate. Am Chem J 1882;3:385-95
   Google Scholar
• Meunier H, Carraz G, Meunier Y, et al. Propriétés pharmacodynamiques de l'acide n-dipropylacetique. Therapie 1963;18:435-8
   PubMedGoogle Scholar
• Henry TR. The history of valproate in clinical neuroscience. Psychopharmacology Bulletin 2003;37(Suppl 2):5-16
   PubMedGoogle Scholar
• British National Formulary March 2008. BMJ group and RPS publishing. London
   Google Scholar
• Brasfield K. Pilot study of divalproex sodium versus valproic acid drug acquisition costs versus all related costs. Curr Ther Res 1999;60:138-44
   Web of Science ®Google Scholar
• Zarate C, Tohen M, Narendran R, et al. The adverse effect profile and efficacy of divalproex sodium compared with valproic acid: a pharmacoepidemiology study. J Clin Psychiatry 1999;60:232-6
   PubMed Web of Science ®Google Scholar
• Löscher W. Serum protein binding and pharmacokinetics of valproate in man, dog, rat and mouse. J Pharmacol Exp Ther 1978;204(2):255-61
   PubMed Web of Science ®Google Scholar
• Depakote data sheet. Available from: http://www.rxlist.com/depakote-drug.htm. [Last accessed 30.10.08]
   Google Scholar
• Bowden CL, Janicak PG, Orsulak P, et al. Relation of serum valproate concentration to response in mania. Am J Psychiatry 1996;153(6):765-70
   PubMed Web of Science ®Google Scholar
• Allen MH, Hirschfeld RM, Wozniak PJ, et al. Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. Am J Psychiatry 2006;163(2):272-5
   PubMed Web of Science ®Google Scholar
• American Psychiatric Assocation: practice guidelines for the treatment of patients with bipolar disorder. Second edition. Am J Psychiatry 2002;159(Suppl)
   Google Scholar
• Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002;16(10):695-714
   PubMed Web of Science ®Google Scholar
• Back DJ, Orme ML. Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet 1990;18(6):472-84
   PubMed Web of Science ®Google Scholar
• DeToledo JC, Haddad H, Ramsay RE. Status epilepticus associated with the combination of valproic acid and clomipramine. Ther Drug Monit 1997;19(1):71-3
   PubMed Web of Science ®Google Scholar
• May TW, Rambeck B, Jürgens U. Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication. Ther Drug Monit 1996;18(5):523-31
   PubMed Web of Science ®Google Scholar
• McCallister-Williams H, Leech SN. Dermatological Syndromes. Chapter 15 in: Adverse syndromes and psychiatric drugs. In: Peter Haddad, Serdar Dursun, Bill Deakin, editors, A Clinical Guide Oxford University Press, Oxford, 2004
   Google Scholar
• Pisani F. Influence of co-medication on the metabolism of valproate. Pharm Weekbl Sci 1992;14(3A):108-13
   PubMedGoogle Scholar
• Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006;61(3):246-55
   PubMed Web of Science ®Google Scholar
• Orr JM, Abbott FS, Farrell K, et al. Interaction between valproic acid and aspirin in epileptic children: serum protein binding and metabolic effects. Clin Pharmacol Ther 1982;31(5):642-9
   PubMed Web of Science ®Google Scholar
• Sandson NB, Marcucci C, Bourke DL, Smith-Lamacchia R. An interaction between aspirin and valproate: the relevance of plasma protein displacement drug-drug interactions. Am J Psychiatry 2006;163(11):1891-6
   PubMed Web of Science ®Google Scholar
• Löscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 2002;16(10):669-94
   PubMed Web of Science ®Google Scholar
• Yatham LN, Liddle PF, Shiah IS, et al. PET study of [(18)F]6-fluoro-L-dopa uptake in neuroleptic- and mood-stabilizer-naive first-episode nonpsychotic mania: effects of treatment with divalproex sodium. Am J Psychiatry 2002;159(5):768-74
   PubMed Web of Science ®Google Scholar
• Yatham LN, Liddle PF, Lam RW, et al. PET study of the effects of valproate on dopamine D(2) receptors in neuroleptic- and mood-stabilizer-naive patients with nonpsychotic mania. Am J Psychiatry 2002;159(10):1718-23
   PubMed Web of Science ®Google Scholar
• Scarna A, Glijsman HJ, McTavish SFB, et al. Effects of a branched-chain amino acid drink in mania. Br J Psychiatry 2003;182:210-213
   PubMed Web of Science ®Google Scholar
• Phiel CJ, Zhang F, Huang EY, et al. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001;276(39):36734-41
   PubMed Web of Science ®Google Scholar
• Akiskal HS, Bourgeois ML, Angst J, et al. Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders. J Affect Disord 2000;59(Suppl 1):S5-S30
   PubMed Web of Science ®Google Scholar
• Davis LL, Bartolucci A, Petty F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord 2005;85(3):259-66
   PubMed Web of Science ®Google Scholar
• Ghaemi SN, Gilmer WS, Goldberg JF, et al. Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study. J Clin Psychiatry 2007;68(12):1840-4
   PubMed Web of Science ®Google Scholar
• Macritchie K, Geddes JR, Scott J, et al. Valproate for acute mood episodes in bipolar disorder. Cochrane Database Syst Rev 2003; Issue 1. Art. No.: CD004052. DOI: 10.1002/14651858.CD004052
   Google Scholar
• McElroy SL, Keck PE, Stanton SP, et al. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J Clin Psychiatry 1996;57(4):142-6
   PubMed Web of Science ®Google Scholar
• Bowden CL, Swann AC, Calabrese JR, et al. A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. J Clin Psychiatry 2006;67(10):1501-10
   PubMed Web of Science ®Google Scholar
• Zajecka JM, Weisler R, Sachs G, et al. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2002;63(12):1148-55
   PubMed Web of Science ®Google Scholar
• Tohen M, Vieta E, Goodwin GM, et al. Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study. J Clin Psychiatry 2008;69(11):1776-89
   PubMed Web of Science ®Google Scholar
• Bowden C, Göğüş A, Grunze H, et al. A 12-week, open, randomized trial comparing sodium valproate to lithium in patients with bipolar I disorder suffering from a manic episode. Int Clin Psychopharmacol 2008;23(5):254-62
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence 2006. Bipolar disorder. The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. Clinical Guideline 38. Available from: www.nice.org.uk
   Google Scholar
• Goodwin GM and Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009 Mar 27. [Epub ahead of print] (http://www.bap.org.uk/publications.php)
   Google Scholar
• Pande AC, Crockatt JG, Janney CA, et al. Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord 2000;2(3 Pt 2):249-55
   PubMed Web of Science ®Google Scholar
• Kushner SF, Khan A, Lane R, Olson WH. Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disorders 2006;8(1):15-27
   PubMed Web of Science ®Google Scholar
• Smith LA, Cornelius V, Warnock A, et al. Acute bipolar mania: a systematic review and meta-analysis of co-therapy vs. monotherapy. Acta Psychiatr Scand 2007;115(1):12-20
   PubMed Web of Science ®Google Scholar
• Müller-Oerlinghausen B, Retzow A, Henn FA, et al. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group. J Clin Psychopharmacol 2000;20(2):195-203
   PubMed Web of Science ®Google Scholar
• Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000;57(5):481-9
   PubMed Web of Science ®Google Scholar
• Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003;160(7):1263-71
   PubMed Web of Science ®Google Scholar
• Tohen M, Calabrese JR, Sachs GS, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006;163(2):247-5
   PubMed Web of Science ®Google Scholar
• Tohen M, Greil W, Calabrese JR, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005;162(7):1281-90
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Shelton MD, Rapport DJ, et al. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry 2005;162(11):2152-61
   PubMed Web of Science ®Google Scholar
• Langosch JM, Drieling T, Biedermann NC, et al. Efficacy of quetiapine monotherapy in rapid-cycling bipolar disorder in comparison with sodium valproate. J Clin Psychopharmacol 2008;28(5):555-60
   PubMed Web of Science ®Google Scholar
• Viguera AC, Nonacs R, Cohen LS, et al. Risk of recurrence of bipolar disorder in pregnant and non-pregnant women after discontinuing lithium maintenance. Am J Psychiatry 2000;157:179-84
   PubMed Web of Science ®Google Scholar
• Wisner KL, Hanusa BH, Peindl KS, Perel JM. Prevention of postpartum episodes in women with bipolar disorder. Biol Psychiatry 2004;56(8):592-6
   PubMed Web of Science ®Google Scholar
• Vieta E, Suppes T, Eggens I, et al. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord 2008;109(3):251-63
   PubMed Web of Science ®Google Scholar
• Tohen M, Chengappa KN, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2003;184:337-45
   Web of Science ®Google Scholar
• Altamura AC, Mundo E, Dell'Osso B, et al. Quetiapine and classical mood stabilizers in the long-term treatment of bipolar disorder: a 4-year follow-up naturalistic study. J Affect Disord 2008;110(1-2):135-41
   PubMed Web of Science ®Google Scholar
• Rendell JM, Juszczak E, Hainsworth J, et al. Developing the BALANCE trial – the role of the pilot study and start-up phase. Bipolar Disord 2004;6(1):26-31
   PubMedGoogle Scholar
• Schwarz C, Volz A, Li C, Leucht S. Valproate for schizophrenia. Cochrane Database Syst Rev 2008; Issue 3. Art. No: CD004028. DOI: 10.1002/14651858.CD004028.pub3
   Google Scholar
• Casey DE, Daniel DG, Wassef AA, et al. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 2003;28(1):182-92
   PubMed Web of Science ®Google Scholar
• Wang H. Combination of magnesium valproate and anti-psychotics in aggressive behaviors of schizophrenics. J Clin Psychosom Dis 2005;11(1):10-1
   Google Scholar
• Yin X-R, Xie B-Q, Jiang L. A double-blind comparative study of sodium valproate in treating of TD. J Clin Psychol Med 2004;14(2):92-3
   Google Scholar
• Lonergan ET, Luxenberg J. Valproate preparations for agitation in dementia. Cochrane Database Syst Rev 2004; Issue 2. Art. No.: CD003945. DOI: 10.1002/14651858.CD003945.pub2
   Google Scholar
• Hollander E, Allen A, Lopez RP, et al. A preliminary double-blind, placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry 2001;62(3):199-203
   PubMed Web of Science ®Google Scholar
• Hollander E, Tracy KA, Swann AC, et al. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology 2003;28(6):1186-97
   PubMed Web of Science ®Google Scholar
• Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry 2002;63(5):442-6
   PubMed Web of Science ®Google Scholar
• Stein DJ, Simeon D, Frenkel M, et al. An open trial of valproate in borderline personality disorder. J Clin Psychiatry 1995;56(11):506-10
   PubMed Web of Science ®Google Scholar
• Kavoussi RJ, Coccaro EF. Divalproex sodium for impulsive aggressive behavior in patients with personality disorder. J Clin Psychiatry 1998;59(12):676-80
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence 2009. Borderline personality disorder: treatment and management. NICE Clinical Guideline 78. Available from: www.nice.org.uk
   Google Scholar
• Adamou M, Puchalska S, Plummer W, Hale AS. Valproate in the treatment of PTSD: systematic review and meta analysis. Curr Med Res Opin 2007;23(6):1285-91
   PubMed Web of Science ®Google Scholar
• Horne M, Lindley SE. Divalproex sodium in the treatment of aggressive behavior and dysphoria in patients with organic brain syndrome. J Clin Psychiatry 1995;56:430-1
   PubMed Web of Science ®Google Scholar
• Wroblewski BA, Joseph AB, Kupfer J, Kalliel K. Effectiveness of valproic acid on destructive and aggressive behaviours in patients with acquired brain injury. Brain Inj 1997;11(1):37-47
   PubMed Web of Science ®Google Scholar
• Fleminger S, Greenwood RJ, Oliver DL. Pharmacological management for agitation and aggression in people with acquired brain injury. Cochrane Database Syst Rev 2006;(4):CD003299
   Google Scholar
• Steiner H, Petersen ML, Saxena K, et al. Divalproex sodium for the treatment of conduct disorder: a randomized controlled clinical trial. J Clin Psychiatry 2003;64(10):1183-91
   PubMed Web of Science ®Google Scholar
• Aliyev NA, Aliyev ZN. Valproate (depakine-chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: randomized, double-blind placebo-controlled study. Eur Psychiatry 2008;23(2):109-14
   PubMed Web of Science ®Google Scholar
• Myrick H, Brady KT, Malcolm R. Divalproex in the treatment of alcohol withdrawal. Am J Drug Alcohol Abuse 2000;26(1):155-60
   PubMed Web of Science ®Google Scholar
• Reoux JP, Saxon AJ, Malte CA, et al. Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial. Alcohol Clin Exp Res 2001;25(9):1324-9
   PubMed Web of Science ®Google Scholar
• Salloum IM, Cornelius JR, Daley DC, et al. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch Gen Psychiatry 2005;62(1):37-45
   PubMed Web of Science ®Google Scholar
• Myrick H, Henderson S, Brady KT, et al. Divalproex loading in the treatment of cocaine dependence. J Psychoactive Drugs. 2001;33(3):283-7
   PubMed Web of Science ®Google Scholar
• Salloum IM, Douaihy A, Cornelius JR, et al. Divalproex utility in bipolar disorder with co-occurring cocaine dependence: a pilot study. Addict Behav. 2007;32(2):410-5
   PubMed Web of Science ®Google Scholar
• Reid MS, Casadonte P, Baker S, et al. A placebo-controlled screening trial of olanzapine, valproate, and coenzyme Q10/L-carnitine for the treatment of cocaine dependence. Addiction. 2005;1001:43-57
   PubMed Web of Science ®Google Scholar
• Minozzi S, Amato L, Davoli M, et al. Anticonvulsants for cocaine dependence. Cochrane Database Syst Rev. 2008;(2):CD006754
   Google Scholar
• Iorio ML, Moretti U, Colcera S, et al. Use and safety profile of antiepileptic drugs in Italy. Eur J Clin Pharmacol 2007;63(4):409-15
   PubMed Web of Science ®Google Scholar
• Perucca E, Meador KJ. Adverse effects of antiepileptic drugs. Acta Neurol Scand Suppl 2005;181:30-5
   PubMedGoogle Scholar
• Appleton RE, Farrell K, Applegarth DA, et al. The high incidence of valproate hepatotoxicity in infants may relate to familial metabolic defects. Can J Neurol Sci 1990;17(2):145-8
   PubMed Web of Science ®Google Scholar
• Lott JA, Bond LW, Bobo RC, et al. Valproic acid-associated pancreatitis: report of three cases and a brief review. Clin Chem 1990;36(2):395-7
   PubMed Web of Science ®Google Scholar
• Underwood TW, Frye CB. Drug-induced pancreatitis. Clin Pharm 1993;12(6):440-8
   PubMedGoogle Scholar
• Acharya S, Bussel JB. Hematologic toxicity of sodium valproate. J Pediatr Hematol Oncol 2000;22(1):62-5
   PubMed Web of Science ®Google Scholar
• Nasreddine W, Beydoun A. Valproate-induced thrombocytopenia: a prospective monotherapy study. Epilepsia 2008;49(3):438-45
   PubMedGoogle Scholar
• Conley EL, Coley KC, Pollock BG, et al. Prevalence and risk of thrombocytopenia with valproic acid: experience at a psychiatric teaching hospital. Pharmacotherapy 2001;21(11):1325-30
   PubMed Web of Science ®Google Scholar
• Wyllie E, Wyllie R. Routine laboratory monitoring for serious adverse effects of antiepileptic medications: the controversy. Epilepsia 1991;32(Suppl 5):S74-9
   PubMed Web of Science ®Google Scholar
• Haddad P. Weight change with atypical antipsychotics in the treatment of schizophrenia. J Psychopharmacol 2005;19(6 Suppl):16-27
   PubMedGoogle Scholar
• Kim JY, Lee HW. Metabolic and hormonal disturbances in women with epilepsy on antiepileptic drug monotherapy. Epilepsia 2007;48(7):1366-70
   PubMed Web of Science ®Google Scholar
• Pylvänen V, Knip M, Pakarinen AJ, et al. Fasting serum insulin and lipid levels in men with epilepsy. Neurology 2003;60(4):571-4
   PubMed Web of Science ®Google Scholar
• Pack AM, Gidal B, Vazquez B. Bone disease associated with antiepileptic drugs. Cleve Clin J Med. 2004;712:S42-8
   PubMed Web of Science ®Google Scholar
• Medicines and Healthcare products Regulatory Agency and Commission on Human Medicines. Antiepileptics: adverse effects on bone. Drug Safety 2009;2(9):2 (http://www.mhra.gov.uk/Publications/Safetyguidance/DrugSafetyUpdate/CON043809)
   Google Scholar
• Rasgon NL, Altshuler LL, Fairbanks L, et al. Reproductive function and risk for PCOS in women treated for bipolar disorder. Bipolar Disord 2005;7:246-59
   PubMed Web of Science ®Google Scholar
• Joffe H, Cohen LS, Suppes T, et al. Valproate is associated with new-onset oligoamenorrhoea with hyperandrogenism in women with bipolar disorder. Biol Psychiatry 2006;59(11):1078-86
   PubMed Web of Science ®Google Scholar
• Joffe H, Cohen LS, Suppes T, et al. Longitudinal follow-up of reproductive and metabolic features of valproate-associated polycystic ovarian syndrome features: a preliminary report. Biol Psychiatry 2006;60(12):1378-8131
   PubMed Web of Science ®Google Scholar
• Sztajnkrycer MD. Valproic acid toxicity: overview and management. J Toxicol Clin Toxicol 2002;40(6):789-801
   PubMed Web of Science ®Google Scholar
• Meador K, Reynolds MW, Crean S, et al. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res 2008;81:1-13
   PubMed Web of Science ®Google Scholar
• Perucca E. Birth defects after prenatal exposure to antiepileptic drugs. Lancet Neurol 2005;4:781-6
   PubMed Web of Science ®Google Scholar
• Wide K, Winbladh B, Kallen B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatrica 2004;93:174-6
   PubMed Web of Science ®Google Scholar
• Samren EB, Duijn CM, Koch S, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis. Epilepsia 1997;38:981-990
   PubMed Web of Science ®Google Scholar
• Michell LE, Adzick JM, Pasquariello PS, et al. Spina bifida. Lancet 2004;364:1885-95
   PubMed Web of Science ®Google Scholar
• Matalon S, Schechtman S, Goldzweig G, et al. The teratogenic effect of carbamazepine: a meta-analysis of 1255 exposures. Reprod Toxicol 2002;16:9-17
   PubMed Web of Science ®Google Scholar
• Lumley J, Watson L, Watson M, et al. 2001. Periconceptional supplementation with folate and/or multivitamins for preventing neural tube defects. Cochrane Database Syst Rev 2001;3:CD001056
   PubMedGoogle Scholar
• Eichholzer M, Tonz O, Zimmermann R. Folic acid: a public-health challenge. Lancet 2006;367:1352-61
   PubMed Web of Science ®Google Scholar
• Department of Health 1992. Folic Acid and the prevention of neural tube defects. Report from an Expert Advisory Group. HMSO, London
   Google Scholar
• Craig J, Morrison P, Morrow J, et al. Failure of periconceptional folic acid to prevent a neural tube defect in the offspring of a mother taking sodium valproate. Seizure 1999;8:253-54
   PubMed Web of Science ®Google Scholar
• Adab N, Kini U, Vinten J, et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2004;75:1575-83
   PubMed Web of Science ®Google Scholar
• Wieck A, Rao S, Sein K, Haddad PM. A survey of antiepileptic prescribing to women of childbearing potential in psychiatry. Arch Womens Ment Health 2007;10(2):83-5
   PubMed Web of Science ®Google Scholar
• Chaudron LH, Jefferson JW. Mood stabilizers during breastfeeding: a review. J Clin Psychiatry 2000;61(2):79-90
   PubMed Web of Science ®Google Scholar
• Reynolds NC Jr, Miska RM. Safety of anticonvulsants in hepatic porphyrias. Neurology 1981;31(4):480-4
   PubMed Web of Science ®Google Scholar
• Swann AC, Bowden CL, Calabrese JR, et al. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania. Am J Psychiatry 1999;156(8):1264-6
   PubMed Web of Science ®Google Scholar
• Keck PE Jr, Calabrese JR, McIntyre RS, et al. Aripiprazole Study Group. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007;68(10):1480-91
   PubMed Web of Science ®Google Scholar
• Macritchie KAN, Young AH. Adverse Syndromes associated with Lithium. Chapter 6 in: P Haddad, S Dursun, B Deakin, editors, Adverse syndromes and psychiatric drugs. Oxford University Press, Oxford 2004
   Google Scholar
• Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 2007;21(11):911-36
   PubMed Web of Science ®Google Scholar
• Anderson IM, Haddad PM, Chaudhry I. Changes in pharmacological treatment for bipolar disorder over time in Manchester: a comparison with Lloyd, et al. (2003). J Psychopharmacology 2004;18(3):441-4
   PubMed Web of Science ®Google Scholar